eli lilly retatrutide trials just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% How Eli Lilly's new weight-loss

The authors summarized recent mechanistic insights and disease-specific evidence across irritable bowel syndrome, inflammatory bowel disease, and neurodegenerative and psychiatric disorders, while critically evaluating emerging EV isolation and analytical technologies in the context of MISEV2023 guidelines

Appetite suppression is common, as shown in a clinical study of semaglutide, where 75% of patients reported decreased appetite, and over time, those behavioral changes translate into measurable laboratory differences

Originated for type 2 diabetes treatment, GLP-1 drugs are now being used to treat obesity because of their potential weight management medicine

Enter Setria L-Glutathione Setria L-Glutathione is a patented, clinically studied form of reduced glutathione